Evidence map›Paper›PMID 40214956›Full record

ArticleMolecular neurobiology2025

A Mendelian randomization study on association of alpha-synuclein and GPNMB with Parkinson's disease risk and progression.

Lizhi Li, Jiabin Liu, Yige Wang, Zhenhua Liu, Qian Xu, Xinxiang Yan, Beisha Tang, Jifeng Guo

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. The combination of theScientific reports · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lizhi LiDepartment of Radiology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Jiabin LiuDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Yige WangDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Zhenhua LiuDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Qian XuDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Xinxiang YanDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Beisha TangDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Jifeng GuoDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China. guojifeng@csu.edu.cn.

Funding

National Key Research and Development Program of China 2021YFC2501204National Natural Science Foundation of China 82071439
6 · The paper itself

Abstract

The prevalence of Parkinson's disease (PD) is increasing due to the aging population. Early diagnosis and prognosis of PD remain challenging, suggesting that seeking appropriate biomarkers for PD is crucial. Glycoprotein nonmetastatic melanoma protein B (GPNMB) and alpha-synuclein (α-syn) have been reported to contribute to PD pathogenesis and are correlated with PD onset and disease progression. We utilized Mendelian randomization (MR) analysis to elucidate the association of GPNMB and α-syn with PD and its disease progression. Six MR approaches were employed, and inverse variance weighted was chosen as the primary method. MR analysis showed that cerebrospinal fluid (CSF) α-syn correlated with Hoehn and Yahr (H&Y) stage and daytime sleepiness suggestively, indicating that CSF α-syn is a promising biomarker for motor symptoms in PD. Furthermore, reverse MR analysis demonstrated an association between PD and α-syn levels in the parietal lobe cortex. Overall, CSF α-syn is a potential biomarker for predicting PD motor symptoms, which requires further studies to validate. However, no associations between GPNMB and PD risk or disease progression were detected.

Indexed as

alpha-SynucleinDisease ProgressionGenetic Predisposition to DiseaseMembrane GlycoproteinsMendelian Randomization AnalysisParkinson DiseaseHumansMalePolymorphism, Single NucleotideRisk Factorsalpha-SynucleinGPNMB protein, humanMembrane GlycoproteinsAlpha-synucleinDisease progressionFinnGenGPNMBMendelian randomizationParkinson’s disease

Identifiers

PMID40214956

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.